

Press Release

Date: 26th May 2006

Words: 306

-Copy starts-

Novexin adds Industry Experts to its Board

Novexin, a company specialising in protein processing technology, is delighted to announce the appointment of Tim McCarthy and James Culverwell as non-executive directors. They will join founders Drs Trevor Jarman, Daniel Jones and Heikki Lanckriet on the Novexin Board.

Tim McCarthy brings to Novexin extensive experience in the biotechnology industry. He has been instrumental in the start up and development of a number of successful biotechnology companies over the past 15 years, including being a founder member of vaccine company Peptide Therapeutics (now Acambis). He was a founder of and is currently Finance Director of biopharmaceutical development company Alizyme.

James Culverwell provides Novexin with over twenty years' experience as a pharmaceutical industry analyst. Until recently he was Global Coordinator for Pharmaceutical Research at leading investment bank, Merrill Lynch and has been involved in a number of small company IPOs and fund raisings. He is now a partner at Sudbrook Associates an FSA regulated corporate advisory company which assists emerging life science businesses with their corporate and strategic development.

Tim McCarthy commented: "Novexin is an exciting and innovative life science company that has developed so rapidly it is already selling its products to customers world-wide. I look forward to helping guide the company to take the right steps to become a leading provider of protein technology."

James Culverwell added: "Novexin is underpinned by a highly talented management team and I plan to assist the company in setting and realising strategic milestones that are key to its continuing corporate development."

Dr Trevor Jarman, CEO of Novexin stated: "We are delighted to welcome Tim and James onto the Novexin Board. They bring a depth of experience to the company which will be invaluable going forward. Their combined business and financial acumen will, I believe, contribute in making Novexin a major commercial success."

-Ends-

For further information, please contact:

Dr Paul Docherty, Sales and Marketing Manager, Novexin Ltd, Babraham Biocubator, Babraham, Cambridge, CB2 4AT, UK.

Tel: +44 (0) 1223 496743 **Fax:** +44 (0) 1223 469741

Email: paul.docherty@novexin.co.uk. **Website:** www.novexin.co.uk.

Editor Contact:

Dr Sue Pearson, International Science Writer, PO Box 170, Hitchin, Hertfordshire SG5 3GD, UK.

Tel/Fax +44 (0) 1462-635327 Email: sue6.pearson@ntlworld.com

Note to Editors**About Novexin**

Novexin, based in Cambridge, UK, is a biotechnology company that is developing and commercialising proprietary protein processing technology originating from the University of Cambridge. This technology, which is commercially available via kits, reagents, licence or Novexin's contract service organisation, addresses the large untapped global need for robust, high-yielding and scalable protein processing and compatible analytical techniques.

Novexin's core 'NVoy' technology involves the use of carbohydrate derivatives that complex with proteins to prevent aggregation, increase stability and decrease the need for detergent use. This technology is finding application in many areas of protein handling including protein purification, refolding, crystallisation and in improved protein analysis including mass spectrometry, nuclear magnetic resonance and circular dichroism.